Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | EVP, Business Operations | June 09, 2023 | June 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date June 09, 2023 · Filed June 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 174,398 |
Ending reported balance
After 2023-06-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-06-09 · Grant · Acquired 24,616 · Balance 125,167 F1: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Row 2 · 2023-06-09 · Grant · Acquired 49,231 · Balance 174,398 F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. |
| Employee Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2030-06-08 | Direct | 161,906 |
Reported balance
After 2023-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-09 · Grant · Acquired 49,231 · Balance 161,906 F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2023 Filed Jun 14, 2023 01:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to buy) · Derivative | 49,231 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001367644-23-000121 · wk-form4_1686705651.xml · derivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,906 Underlying: Common Stock · 49,231 shares Expires 2030-06-08 F3 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 49,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000121 · wk-form4_1686705651.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,398 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 24,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000121 · wk-form4_1686705651.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,167 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 12,308 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001367644-23-000072 · wf-form4_167814943048288.xml · derivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,675 Underlying: Common Stock · 12,308 shares Expires 2030-03-01 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. F2 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 12,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000072 · wf-form4_167814943048288.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,551 F3 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. F2 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 6,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000072 · wf-form4_167814943048288.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,243 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. F2 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 19:41 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 998 | $12.38 | $12,355.24 |
DisclosureSEC source: 0001367644-23-000054 · wf-form4_167778608843186.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,927 F1 · shares: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 01:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 812 | $13.71 | $11,132.52 |
DisclosureSEC source: 0001367644-23-000033 · wf-form4_167754732777822.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,681 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 432 | $14.30 | $6,177.60 |
DisclosureSEC source: 0001367644-23-000033 · wf-form4_167754732777822.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,493 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 01:34 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,964 | $13.25 | $26,023.00 |
DisclosureSEC source: 0001367644-23-000013 · wf-form4_167607925563475.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,925 F2 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 01:34 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 95 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000013 · wf-form4_167607925563475.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,889 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2022 fiscal year, as certified by the Compensation Committee following the performance period. On February 08, 2023, the final certification date, the Compensation Committee certified the achievement of the 2020-2022 PSUs at a payout factor of 101.67% of target resulting in the actual award of 5,792 shares of common stock, which is in excess of the 5,697 shares previously reported on February 25, 2020. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 42,289 | $41.38 Strike: $41.38 | $1,749,918.82 |
DisclosureSEC source: 0001367644-22-000043 · wf-form4_164626708631194.xml · derivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,289 Underlying: Common Stock · 42,289 shares Expires 2029-02-28 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 17,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000043 · wf-form4_164626708631194.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,939 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 32,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000043 · wf-form4_164626708631194.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,117 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest either in three equal annual installments beginning on the day prior to the first anniversary of the date of grant (10,573 shares) or on the day prior to the second anniversary date of the grant (21,750 shares), assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 739 | $39.64 | $29,293.96 |
DisclosureSEC source: 0001367644-22-000043 · wf-form4_164626708631194.xml · nonDerivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,200 F3 · security: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 828 | $42.47 | $35,165.16 |
DisclosureSEC source: 0001367644-22-000030 · wf-form4_164582741558623.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,794 F1 · security: Represents shares of common stock withheld by the company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 424 | $42.23 | $17,905.52 |
DisclosureSEC source: 0001367644-22-000030 · wf-form4_164582741558623.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,622 F1 · security: Represents shares of common stock withheld by the company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 23:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,980 | $42.23 | $83,615.40 |
DisclosureSEC source: 0001367644-22-000016 · wf-form4_164574658105150.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,046 F2 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 23:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 1,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000016 · wf-form4_164574658105150.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,026 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. On February 22, 2022, the final certification date, the Compensation Committee certified the achievement of the 2019-2021 PSUs at a payout factor of 136.14% of target resulting in the actual award of 6,917 shares of common stock, which is in excess of the 5,081 shares previously reported on February 28, 2019. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 20,145 | $99.02 Strike: $49.64 | $1,994,757.90 |
DisclosureSEC source: 0001367644-21-000049 · wf-form4_161481282979100.xml · derivative · entry 6 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,145 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F3 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.01 to $99.99. F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 17,134 | $99.62 Strike: $30.63 | $1,706,889.08 |
DisclosureSEC source: 0001367644-21-000049 · wf-form4_161481282979100.xml · derivative · entry 5 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,134 shares Expires 2024-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.05 to $100.25. F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,145 | $99.02 | $1,994,757.90 |
DisclosureSEC source: 0001367644-21-000049 · wf-form4_161481282979100.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,190 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F3 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.01 to $99.99. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,145 | $49.64 | $999,997.80 |
DisclosureSEC source: 0001367644-21-000049 · wf-form4_161481282979100.xml · nonDerivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 17,134 | $99.62 | $1,706,889.08 |
DisclosureSEC source: 0001367644-21-000049 · wf-form4_161481282979100.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,190 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.05 to $100.25. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 17,134 | $30.63 | $524,814.42 |
DisclosureSEC source: 0001367644-21-000049 · wf-form4_161481282979100.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 732 | $97.15 | $71,113.80 |
DisclosureSEC source: 0001367644-21-000047 · wf-form4_161437785866552.xml · nonDerivative · entry 5 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,190 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 739 | $97.15 | $71,793.85 |
DisclosureSEC source: 0001367644-21-000047 · wf-form4_161437785866552.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,922 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 14,973 | $93.49 Strike: $93.49 | $1,399,825.77 |
DisclosureSEC source: 0001367644-21-000047 · wf-form4_161437785866552.xml · derivative · entry 6 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,973 Underlying: Common Stock · 14,973 shares Expires 2028-02-23 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 847 | $93.49 | $79,186.03 |
DisclosureSEC source: 0001367644-21-000047 · wf-form4_161437785866552.xml · nonDerivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,661 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 3,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000047 · wf-form4_161437785866552.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,508 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 3,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000047 · wf-form4_161437785866552.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,764 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:24 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,183 | $123.45 | $269,491.35 |
DisclosureSEC source: 0001367644-21-000018 · wf-form4_161309662486709.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,020 F3 · security: Represents shares of common stock withheld to pay taxes due upon vesting of the PSUs. F2 · balance_after: The number of derivative securities beneficially owned was adjusted to account for a change in previously reported PSUs. 4,285 PSUs were previously reported, of which only 2,714 vested on February 11, 2020. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:24 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000018 · wf-form4_161309662486709.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,203 F1 · security: Consists of Performance Stock Units ("PSUs") previously granted on February 27, 2018 under the company's stock incentive plan as amended and restated. Each PSU represents the right to receive one share of common stock, which vested at a specified percentage based upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2020 fiscal year, as certified by the Compensation Committee following the performance period. On February 9, 2021, the Compensation Committee certified the achievement of the 2018-2020 PSUs at a payout factor of 150% of target resulting in the actual award of 7,554 shares of common stock, which is in excess of the 5,036 shares previously reported on March 1, 2018. F1 · shares: Consists of Performance Stock Units ("PSUs") previously granted on February 27, 2018 under the company's stock incentive plan as amended and restated. Each PSU represents the right to receive one share of common stock, which vested at a specified percentage based upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2020 fiscal year, as certified by the Compensation Committee following the performance period. On February 9, 2021, the Compensation Committee certified the achievement of the 2018-2020 PSUs at a payout factor of 150% of target resulting in the actual award of 7,554 shares of common stock, which is in excess of the 5,036 shares previously reported on March 1, 2018. F2 · balance_after: The number of derivative securities beneficially owned was adjusted to account for a change in previously reported PSUs. 4,285 PSUs were previously reported, of which only 2,714 vested on February 11, 2020. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleStock Options (Right to Buy) · Derivative | 17,009 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001367644-20-000037 · wf-form4_158750711233940.xml · derivative · entry 6 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,384 Underlying: Common Stock · 17,009 shares Expires 2023-02-28 F2 · security: Consists of options granted under the company's stock incentive plan as amended and restated. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 17,009 | $69.00 | $1,173,621.00 |
DisclosureSEC source: 0001367644-20-000037 · wf-form4_158750711233940.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,256 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 17,009 | $30.86 | $524,897.74 |
DisclosureSEC source: 0001367644-20-000037 · wf-form4_158750711233940.xml · nonDerivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleStock Options (Right to Buy) · Derivative | 20,414 | $0.00 Strike: $26.45 | $0.00 |
DisclosureSEC source: 0001367644-20-000037 · wf-form4_158750711233940.xml · derivative · entry 5 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,393 Underlying: Common Stock · 20,414 shares Expires 2022-03-09 F2 · security: Consists of options granted under the company's stock incentive plan as amended and restated. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,414 | $65.00 | $1,326,910.00 |
DisclosureSEC source: 0001367644-20-000037 · wf-form4_158750711233940.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,256 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 22:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,414 | $26.45 | $539,950.30 |
DisclosureSEC source: 0001367644-20-000037 · wf-form4_158750711233940.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| April 06, 2020 Filed Apr 9, 2020 00:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,730 | $60.00 | $223,800.00 |
DisclosureSEC source: 0001367644-20-000035 · wf-form4_158639171266875.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,256 F2 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| April 06, 2020 Filed Apr 9, 2020 00:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 4,242 | $60.00 | $254,520.00 |
DisclosureSEC source: 0001367644-20-000035 · wf-form4_158639171266875.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,986 F1 · shares: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 409 | $58.42 | $23,893.78 |
DisclosureSEC source: 0001367644-20-000019 · wf-form4_158285658301395.xml · nonDerivative · entry 5 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,228 F3 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 484 | $59.91 | $28,996.44 |
DisclosureSEC source: 0001367644-20-000019 · wf-form4_158285658301395.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,637 F3 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 513 | $59.91 | $30,733.83 |
DisclosureSEC source: 0001367644-20-000019 · wf-form4_158285658301395.xml · nonDerivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,121 F3 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 22,784 | $61.44 Strike: $61.44 | $1,399,848.96 |
DisclosureSEC source: 0001367644-20-000019 · wf-form4_158285658301395.xml · derivative · entry 6 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,105 Underlying: Common Stock · 22,784 shares Expires 2027-02-24 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000019 · wf-form4_158285658301395.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,634 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue for the 2020 - 2022 fiscal years, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000019 · wf-form4_158285658301395.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,937 F1 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 21:10 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,430 | $56.93 | $138,339.90 |
DisclosureSEC source: 0001567619-19-006788 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,240 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 23:40 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,024 | $58.20 | $117,796.80 |
DisclosureSEC source: 0001567619-19-006067 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,670 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:38 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 812 | $58.71 | $47,672.52 |
DisclosureSEC source: 0001567619-19-005679 · doc1.xml · nonDerivative · entry 5 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,713 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.